BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29878857)

  • 1. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
    Ezeh U; Huang A; Landay M; Azziz R
    J Womens Health (Larchmt); 2018 Jul; 27(7):892-902. PubMed ID: 29878857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
    Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
    Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for hirsutism (excluding laser and photoepilation therapy alone).
    van Zuuren EJ; Fedorowicz Z; Carter B; Pandis N
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010334. PubMed ID: 25918921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.
    Fraison E; Kostova E; Moran LJ; Bilal S; Ee CC; Venetis C; Costello MF
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD005552. PubMed ID: 32794179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Maier PS; Mattiello SS; Lages L; Spritzer PM
    Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
    Lepine S; Jo J; Metwally M; Cheong YC
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD009526. PubMed ID: 29125183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin and Teupolioside attenuate signs and symptoms severity associated to hirsutism in PCOS women: a preliminary pilot study.
    Malvasi A; Tinelli A; Dellino M; Trojano G; Vinciguerra M; Mina M
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6187-6191. PubMed ID: 36111918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
    Amiri M; Kabir A; Nahidi F; Shekofteh M; Ramezani Tehrani F
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):64-77. PubMed ID: 29457756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial.
    Moretti C; Guccione L; Di Giacinto P; Simonelli I; Exacoustos C; Toscano V; Motta C; De Leo V; Petraglia F; Lenzi A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):824-838. PubMed ID: 29211888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
    van Zuuren EJ; Fedorowicz Z
    Br J Dermatol; 2016 Jul; 175(1):45-61. PubMed ID: 26892495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
    Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Farquhar C; Lee O; Toomath R; Jepson R
    Cochrane Database Syst Rev; 2003; (4):CD000194. PubMed ID: 14583916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
    Maier PS; Spritzer PM
    Gynecol Obstet Invest; 2012; 74(2):136-42. PubMed ID: 22889864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.